Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 10, 2008, Pages 1093-1099

  Derex, L ^a,b   Nighoghossian, N ^a,b  

^a HÔPITAL NEUROLOGIQUE   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; GELATINASE B; GLUCOSE; HEPARIN; STREPTOKINASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ATTENTION; BIOLOGY; BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BRAIN; BRAIN HEMORRHAGE; BRAIN VEIN; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HEMATOMA; HOSPITAL ADMISSION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; KNOWLEDGE; LEUKOARAIOSIS; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; MIDDLE CEREBRAL ARTERY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PERFUSION WEIGHTED IMAGING; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RATING SCALE; REVIEW; RISK; SCORING SYSTEM;

EID: 53149124792     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2007.133371     Document Type: Review

References (87)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Reeves MJ, Arora S, Broderick JP, et al. Acute stroke care in the US: results from the 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke 2005;36:1232-40.
3. Caplan LR. Stroke thrombolysis: slow progress. Circulation 2006;114:187-90.
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-18.
5. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study, a randomized controlled trial: Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;21:2019-26.
6. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
7. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study: a randomized controlled trial. JAMA 1999;282:2003-11.
8. Jaillard A, Comu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E Study. Stroke 1999;30:1326-32.
9. Kase CS, Furlan AJ, Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke. The PROACT II trial. Neurology 2001;57:1603-10
10. Kidwell CS, Saver JL, Carneado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke 2002;33:717-24.
11. Derex L, Hermier M, Adeleine P, et al. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry 2005;76:70-5.
12. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 2006;37:556-61.
13. The IMS Study Investigators. Hemorrhage in the Interventional Management of Stroke study. Stroke 2006;37:847-51.
14. Graham GO. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847-50.
15. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOSTj: an observational Study. Lancet 2007;369:275-82.
16. Del Zoppo GJ, von Kummer R, Hamann GF. Ischaemic damage of brain microvessels: inherent risks for thrombolytic treatment in stroke. J Neurol Neurosurg Psychiatry 1998;65:1-9.
17. Del Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986;7:595-607.
18. Hu B, Liu C, Zivin JA. Reduction of intracerebral hemorrhage in a rabbit embolic stroke model. Neurology 1999;53:2140-5.
19. Asahi M, Asahi K, Wang X, et al. Reduction of tissue plasminogen activator induced hemorrhage and brain injury by free radical spin trapping after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000;20:452-7.
20. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPS are associated with blood brain barrier opening after reperfusion in rat brain. Stroke 1998;29:2189-95.
21. Asahi M, Wang X, Mori T, et al. Effects of matrix metalloproteinase-9 gene knockout on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001;21:7724-32.
22. Gautier S, Petrault O, Gele P, et al. Involvement of thrombolysis in recombinant tissue plasminogen activator-induced cerebral hemorrhages and effect on infarct volume and postischemic endothelial function. Stroke 2003;34:2975-9.
23. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thromborysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002;33:831-6.
24. Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats. Inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 1998;29:1020-30.
25. Montaner J, Alvarez-Sabin J, Molina C, et al. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001;32:1759-66.
26. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.
27. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34:40-6
28. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000;31:3034-40.
29. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017-26.
30. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997;28:957-60.
31. Larrue V, von Kummer R, Müller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-41.
32. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999;30:2280-4.
33. Kidwell CS, Chalela JA, Saver JL, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA 2004;292:1823-30.
34. linger EC, Cohen MS, Brown TR. Gradient-echo imaging of hemorrhage at 1.5 Tesla. Magn Reson Imaging 1989;7:163-72.
35. *-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol. 1999;20:637-42.
36. Brott TG, Adams HP Jr. Olinger CP, et al. Measurements of acute cerebral infarction. A clinical examination scale. Stroke 1989;20:864-70.
37. Molina CA, Montaner J, Abilleira S, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke 2001;32:2821-7.
38. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue. Asymptomatic or symptomatic? Stroke 2001;32:1330-5.
39. Cocho D, Borrell M, Marti-Fabregas J, et al. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke 2006;37:996-9.
40. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
41. Levy D, Brott T, Haley EC Jr, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994;25:291-7.
42. Haley EC Jr, Lyden PD, Johnston KC, et al. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke 2005;36:1109-10.
43. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
44. Itoh Y, Yamada M, Hayakawa M, et al. Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar hemorrhage in the elderly. J Neurol Sci 1993;116:135-41.
45. Vonsattel JP, Myers RH, Hedley-Whyte ET, et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: a comparative histological study. Ann Neurol 1991;30:637-49.
46. Sylaja PN, Cote R, Buchan AM, et al. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006;77:826-9.
47. Tanne D, Gorman MJ, Bates VE, et al. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA Stroke Survey experience. Stroke 2000;31:370-5.
48. The MAST-ltaly Investigators. Risk factors in the MAST-ltaly trial. Cerebrovasc Dis 1996;6:181.
49. Tanne D, Kasner SE, Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice. Circulation 2002;105:1679-85.
50. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis: mortality and functional outcomes in the GUSTO-I Trial. Circulation 1995;92:2811-18.
51. Demchuk AM, Morgenstern LB, Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999;30:34-9.
52. Lindsberg PJ, Soinne L, Roine RO, et al. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003;34:1443-9.
53. Hamann GF, del Zoppo GJ, von Kummer R. Hemorrhagic transformation of cerebral infarction: possible mechanisms. Thromb Haemost 1999;82:92-4.
54. Castellanos M, Leira R, Serena J, et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004;35:1671-6.
55. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004;35:2123-7.
56. Von Kummer R. Early major ischemic changes on computed tomography should preclude use of tissue plasminogen activator. Stroke 2003;34:820-1.
57. Lyden P. Early major ischemic changes on computed tomography should not preclude use of tissue plasminogen activator. Stroke 2003;34:821-2.
58. Patel SC, Levine SR, Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830-8.
59. Roberts HC, Dillon WP, Furlan AJ, et al. Computed tomographic findings in patients undergoing intra-arterial thrombolysis for acute ischemic stroke due to middle cerebral artery occlusion: results from the PROACT II trial. Stroke 2002;33:1565-7.
60. Gilligan AK, Markus R, Read S, et al. Baseline blood pressure but not early computed tomography changes predicts major hemorrhage after streptokinase in acute ischemic stroke. Stroke 2002;33:2236- 42.
61. Grotta JC, Chiu D, Lu M, et al. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke 1999;30:1528-33.
62. Kalafut MA, Schriger DL, Saver JL, et al. Detection of early CT signs of > 1/3 middle cerebral artery infarctions: interrater reliability and sensitivity of CT interpretation by physicians involved in acute stroke care. Stroke 2000;31:1667-71.
63. Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 2000;355:1670-4.
64. Leys D, Pruvo JP, Godefroy O, et al. Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke 1992;23:317-24.
65. Tong DC, Adami A, Moseley ME, et al. Relationship between apparent diffusion coefficient and subsequent hemorrhagic transformation following acute ischemic stroke. Stroke 2000;31:2378-84.
66. Tong DC, Adami A, Moseley ME, et al. Prediction of hemorrhagic transformation following stroke. Arch Neurol 2001;58:587-93.
67. Selim M, Fink JN, Kumar S, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke 2002;33:2047-52.
68. Kidwell CS, Saver JL, Villablanca P, et al. Magnetic resonance imaging detection of microbleeds before thrombolysis. An emerging application. Stroke 2002;33:95-8.
69. Oppenheim C, Samson Y, Dormont D, et al. DWI prediction of symptomatic hemorrhagic transformation in acute MCA infarct. J Neuroradiol 2002;29:6-13.
70. Alsop DC, Makovetskaya E, Kumar S, et al. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke 2005;36:746-50.
71. Albers GW, Thijs VN, Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol 2006;60:508-17.
72. Lansberg MG, Thijs VN, Bammer R, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007;38:2275-8.
73. Kassner A, Roberts T, Taylor K, et al. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol 2005;26:2213-17.
74. Latour LL, Kang DW, Ezzedine M, et al. Early blood-brain barrier disruption in human focal brain ischemia. Ann Neurol 2004;56:468-77.
75. *-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator. J Cereb Blood Flow Metab 2003;23:1362-70.
76. Ohta H, Nakano S, Yokogami K, et al. Appearance of early venous filling during intraarterial reperfusion therapy for acute middle cerebral artery occlusion. A predictive sign for hemorrhagic complications. Stroke 2004;35:893-8.
77. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006;37:2463-6.
78. *-weighted brain MRI study. Stroke 2002;33:735-42.
79. Fan YH, Zhang L, Lam WWM, et al. Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. Stroke 2003;34:2459-62.
80. Chalela JA, Kang DW, Warach S. Multiple cerebral microbleeds: MRI marker of a diffuse hemorrhage-prone state. J Neuroimaging 2004;14:54-7.
81. Derex L, Nighoghossian N, Hermier M, et al. Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis 2004;17:238-41.
82. Kakuda W, Thijs VN, Lansberg MG, et al. Clinical importance of microbleeds in patients receiving IV thrombolysis. Neurology 2005;65:1175-8.
83. *-weighted magnetic resonance imaging data from 570 patients. Stroke 2007;38:2738-44.
84. Thomalla G, Sobesky J, Köhrmann M, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia. MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 2007;38:313-18.
85. Trouillas P, Derex L, Philippeau F, et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rtPA thrombolysis. A study in 157 cases. Stroke 2004;35:1323-8.
86. Thomalla G, Schwark C, Sobesky J, et al. Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients. Comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006;37:852-8.
87. Kohrmann M, Juttler E, Fiebach JB, et al. MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurol 2006;5:661-7.